Top 10 Drugs
- Aust Prescr 2007;30:140
- 1 December 2007
- DOI: 10.18773/austprescr.2007.085
|*||The defined daily dose (DDD)/thousand population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people, in every thousand Australians, are taking the standard dose of a drug every day.|
|†||Based on date of supply|
|‡||PBS Pharmaceutical Benefits Scheme, RPBS Repatriation Pharmaceutical Benefits Scheme|
|§||Combination drugs do not have a DDD allocated|
Source: Drug Utilisation Sub-Committee (DUSC) Drug Utilisation Database, as at 11 October 2007.
Strontium ranelate: The PBS listing for the osteoporosis drug strontium ranelate has been extended to allow treatment of postmenopausal women without an existing fracture and a bone mineral density T-score ≤ -3.0 (primary prevention). The latest issue of NPS RADAR describes the place in therapy of strontium relative to other anti-resorptive agents.
It also contains information on:
See the complete reviews at www.npsradar.org.au